NYSE:BAXBaxter International Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Baxter International Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $83.08 -3.30 (-3.82 %) (As of 08/3/2020 04:00 PM ET) Add Compare Share Today's Range$83.08Now: $83.08▼$87.1150-Day Range$82.47MA: $86.00▼$90.7352-Week Range$69.10Now: $83.08▼$95.19Volume330,903 shsAverage Volume2.75 million shsMarket Capitalization$42.06 billionP/E Ratio25.10Dividend Yield1.13%Beta0.82 ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingBaxter International has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 14 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $96.94, Baxter International has a potential upside of 16.7% from its current price of $83.08.Amount of Analyst CoverageBaxter International has only been the subject of 4 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesBaxter International has received 683 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBaxter International has received 593 “underperform” votes. (Add your “underperform” vote.)Community SentimentBaxter International has received 53.53% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Baxter International and other stocks. Vote “Outperform” if you believe BAX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BAX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 1.7 Dividend Strength Dividend YieldBaxter International has a dividend yield of 1.13%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthBaxter International has only been increasing its dividend for 3 years.Dividend CoverageThe dividend payout ratio of Baxter International is 29.61%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Baxter International will have a dividend payout ratio of 26.70% next year. This indicates that Baxter International will be able to sustain or increase its dividend. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Baxter International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,613,932.00 in company stock.Percentage Held by InsidersOnly 0.13% of the stock of Baxter International is held by insiders.Percentage Held by Institutions83.74% of the stock of Baxter International is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Baxter International are expected to grow by 19.54% in the coming year, from $3.07 to $3.67 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Baxter International is 25.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.59.Price to Earnings Ratio vs. SectorThe P/E ratio of Baxter International is 25.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.94.Price to Earnings Growth RatioBaxter International has a PEG Ratio of 2.74. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBaxter International has a P/B Ratio of 5.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 2.7Dividend Strength: 1.7Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.80 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:BAX Previous Symbol CUSIP07181310 CIK10456 Webwww.baxter.com Phone224-948-2000Debt Debt-to-Equity Ratio0.80 Current Ratio2.97 Quick Ratio2.31Price-To-Earnings Trailing P/E Ratio25.10 Forward P/E Ratio27.06 P/E Growth2.74 Sales & Book Value Annual Sales$11.36 billion Price / Sales3.70 Cash Flow$4.78 per share Price / Cash Flow17.38 Book Value$15.50 per share Price / Book5.36Profitability EPS (Most Recent Fiscal Year)$3.31 Net Income$1.00 billion Net Margins8.10% Return on Equity20.75% Return on Assets8.81%Miscellaneous Employees50,000 Outstanding Shares506,230,000Market Cap$42.06 billion Next Earnings Date10/29/2020 (Estimated) OptionableOptionable $83.08 -3.30 (-3.82 %) (As of 08/3/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BAX News and Ratings via Email Sign-up to receive the latest news and ratings for BAX and its competitors with MarketBeat's FREE daily newsletter. Baxter International (NYSE:BAX) Frequently Asked Questions How has Baxter International's stock been impacted by COVID-19 (Coronavirus)? Baxter International's stock was trading at $77.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BAX stock has increased by 6.6% and is now trading at $83.08. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Baxter International? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Baxter International. When is Baxter International's next earnings date? Baxter International is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020. View our earnings forecast for Baxter International. How were Baxter International's earnings last quarter? Baxter International Inc (NYSE:BAX) posted its quarterly earnings results on Thursday, July, 30th. The medical instruments supplier reported $0.64 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.71 by $0.07. The medical instruments supplier had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.86 billion. Baxter International had a net margin of 8.10% and a return on equity of 20.75%. The firm's revenue for the quarter was down 4.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.89 EPS. View Baxter International's earnings history. How often does Baxter International pay dividends? What is the dividend yield for Baxter International? Baxter International announced a quarterly dividend on Tuesday, July 14th. Shareholders of record on Monday, August 31st will be given a dividend of $0.245 per share on Thursday, October 1st. This represents a $0.98 dividend on an annualized basis and a dividend yield of 1.18%. The ex-dividend date of this dividend is Friday, August 28th. View Baxter International's dividend history. How will Baxter International's stock buyback program work? Baxter International announced that its board has initiated a share buyback plan on Tuesday, November 13th 2018, which allows the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 6.1% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its shares are undervalued. What guidance has Baxter International issued on next quarter's earnings? Baxter International updated its FY20 earnings guidance on Thursday, July, 30th. The company provided earnings per share guidance of $3.00-3.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.31. The company issued revenue guidance of (1%) - 1% to $11.6-11.8 billion, compared to the consensus revenue estimate of $11.71 billion. What price target have analysts set for BAX? 18 analysts have issued 1 year price targets for Baxter International's stock. Their forecasts range from $84.00 to $105.00. On average, they anticipate Baxter International's stock price to reach $96.94 in the next twelve months. This suggests a possible upside of 16.7% from the stock's current price. View analysts' price targets for Baxter International. Has Baxter International been receiving favorable news coverage? News coverage about BAX stock has trended somewhat positive on Monday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Baxter International earned a news impact score of 1.6 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Baxter International. Are investors shorting Baxter International? Baxter International saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 5,190,000 shares, an increase of 12.3% from the June 30th total of 4,620,000 shares. Based on an average daily volume of 2,850,000 shares, the days-to-cover ratio is currently 1.8 days. Approximately 1.0% of the company's shares are sold short. View Baxter International's Current Options Chain. Who are some of Baxter International's key competitors? Some companies that are related to Baxter International include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), Varian Medical Systems (VAR), ABIOMED (ABMD) and Steris (STE). View all competitors. What other stocks do shareholders of Baxter International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Baxter International investors own include CA (CA), Johnson & Johnson (JNJ), Honeywell International (HON), Cisco Systems (CSCO), AT&T (T), Pfizer (PFE), BlackRock (BLK), Verizon Communications (VZ), Abbott Laboratories (ABT) and Procter & Gamble (PG). Who are Baxter International's key executives? Baxter International's management team includes the following people: Mr. José E. Almeida, Chairman, Pres & CEO (Age 57)Mr. James K. Saccaro, Exec. VP & CFO (Age 46)Mr. Sean Martin, Sr. VP & Gen. Counsel (Age 56)Mr. Giuseppe Accogli, Sr. VP & Pres of Americas (Age 48)Mr. Scott Pleau, Sr. VP of Operations (Age 53) What is Baxter International's stock symbol? Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX." Who are Baxter International's major shareholders? Baxter International's stock is owned by many different retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.43%), Robeco Institutional Asset Management B.V. (0.22%), Prudential PLC (0.15%), New York State Teachers Retirement System (0.13%), Marathon Asset Management LLP (0.13%) and PGGM Investments (0.13%). Company insiders that own Baxter International stock include Albert P L Stroucken, Andrew Frye, Carole J Shapazian, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, John D Forsyth, Peter S Hellman, Scott Pleau, Sean Martin, Third Point Llc and Thomas T Stallkamp. View institutional ownership trends for Baxter International. Which major investors are selling Baxter International stock? BAX stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Calamos Advisors LLC, Marathon Asset Management LLP, Ziegler Capital Management LLC, Robeco Institutional Asset Management B.V., Dalton Greiner Hartman Maher & Co., Raymond James & Associates, and Envestnet Asset Management Inc.. Company insiders that have sold Baxter International company stock in the last year include Albert P L Stroucken, Andrew Frye, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, and John D Forsyth. View insider buying and selling activity for Baxter International. Which major investors are buying Baxter International stock? BAX stock was bought by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, PGGM Investments, Fulton Breakefield Broenniman LLC, Railway Pension Investments Ltd, First Trust Advisors LP, Rhenman & Partners Asset Management AB, Ardevora Asset Management LLP, and Oregon Public Employees Retirement Fund. View insider buying and selling activity for Baxter International. How do I buy shares of Baxter International? Shares of BAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Baxter International's stock price today? One share of BAX stock can currently be purchased for approximately $83.08. How big of a company is Baxter International? Baxter International has a market capitalization of $42.06 billion and generates $11.36 billion in revenue each year. The medical instruments supplier earns $1.00 billion in net income (profit) each year or $3.31 on an earnings per share basis. Baxter International employs 50,000 workers across the globe. What is Baxter International's official website? The official website for Baxter International is www.baxter.com. How can I contact Baxter International? Baxter International's mailing address is One Baxter Parkway DF2-1W, Deerfield IL, 60015. The medical instruments supplier can be reached via phone at 224-948-2000 or via email at [email protected] This page was last updated on 8/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
